Relationship between of Exon 3 (+/-) Genotypes of Growth Hormone Receptor and Metabolic Risk Factors in Patients in Pre-diabetic State

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Clinical Biochemistry, School of Allied Medical Science, Ilam University of Medical Sciences, Ilam, Iran

2 Department of Biology, School of Basic Sciences, Islamic Azad University, Kurdistan Science and Research Branch, Sanandaj, Iran

3 Assistant Professor, Department of Biology, School of Basic Sciences, Islamic Azad University, Sanandaj Branch, Sanandaj, Iran

Abstract

Background: Metabolic impacts of two important alleles of trh growth hormone receptors (GHR), one with retention of exon 3 [exon 3 (+) GHR] and the other with the deletion of it [exon 3 (-) GHR], on the metabolic risk factors of type 2 diabetes mellitus (T2DM) are really unknown. We aimed to evaluate relationships between the genotypes and metabolic risk factors of T2DM.Methods: 40 patients in pre-diabetic state and 40 healthy subjects were selected based on their clinical and laboratory evidence. For genotyping, DNA was extracted from the leukocytes of peripheral blood and amplified by multiplex polymerase chain reaction method. Genotypes of the amplified DNA samples were resolved using 1.5% agarose gel electrophoresis. Other risk factors were also determined by using standard methods and appropriate kits.Findings: Frequency of the homozygote exon 3 retained genotype [exon 3 (+/+) GHR] was significantly higher in the subject in pre-diabetic state (P < 0.0001); the frequency of exon 3 (+/-) GHR and exon 3 (-/-) GHR genotypes were significantly higher in the control subjects (P = 0.0003). The decrease of metabolic risk factors was profound in subjects with exon 3(-/-) GHR genotypeConclusion: The presence of exon 3 deleted allele of GHR, especially in the homozygosity situation, was associated with decreased levels of the metabolic risk factors of type 2 diabetes mellitus. So, the exon 3 deleted GHR may have more robust biological and metabolic activities lead to the resistance against T2DM.

Keywords


  1. Dominici FP, Argentino DP, Munoz MC, Miquet JG, Sotelo AI, Turyn D. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 2005; 15(5): 324-36.
  2. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330(6148): 537-43.
  3. Postel-Vinay MC, Kelly PA. Growth hormone receptor signalling. Baillieres Clin Endocrinol Metab 1996; 10(3): 323-36.
  4. Baumann G, Stolar MW, Amburn K, Barsano CP, DeVries BC. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab 1986; 62(1): 134-41.
  5. Sotiropoulos A, Goujon L, Simonin G, Kelly PA, Postel-Vinay MC, Finidori J. Evidence for generation of the growth hormone-binding protein through proteolysis of the growth hormone membrane receptor. Endocrinology 1993; 132(4): 1863-5.
  6. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 2000; 141(12): 4342-8.
  7. Takagi K, Saito Y, Sawada J. Proteasome inhibitor enhances growth hormone-binding protein release. Mol Cell Endocrinol 2001; 182(2): 157-63.
  8. Urbanek M, MacLeod JN, Cooke NE, Liebhaber SA. Expression of a human growth hormone (hGH) receptor isoform is predicted by tissue-specific alternative splicing of exon 3 of the hGH receptor gene transcript. Mol Endocrinol 1992; 6(2): 279-87.
  9. Dos SC, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004; 36(7): 720-4.
  10. Strawbridge RJ, Karvestedt L, Li C, Efendic S, Ostenson CG, Gu HF, et al. GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder. Growth Horm IGF Res 2007; 17(5): 392-8.
  11. Seidel B, Glasow A, Schutt M, Kiess W, Wu Z, Strasburger CJ, et al. Association between the GH receptor/exon 3 genotype and the level of exon 3-positive GH-binding protein in human serum. Eur J Endocrinol 2003; 148(3): 317-24.
  12. Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, Amselem S. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. J Clin Endocrinol Metab 2003; 88(4): 1705-10.
  13. Urbanek M, Russell JE, Cooke NE, Liebhaber SA. Functional characterization of the alternatively spliced, placental human growth hormone receptor. J Biol Chem 1993; 268(25): 19025-32.
  14. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 2000; 275(25): 18664-9.
  15. Mercado M, Gonzalez B, Sandoval C, Esquenazi Y, Mier F, Vargas G, et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 2008; 93(9): 3411-5.
  16. Sorensen K, Aksglaede L, Munch-Andersen T, Aachmann-Andersen NJ, Leffers H, Helge JW, et al. Impact of the growth hormone receptor exon 3 deletion gene polymorphism on glucose metabolism, lipids, and insulin-like growth factor-I levels during puberty. J Clin Endocrinol Metab 2009; 94(8): 2966-9.
  17. Kamenicky P, Dos SC, Espinosa C, Salenave S, Galland F, Le BY, et al. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Eur J Endocrinol 2009; 161(2): 231-5.
  18. Binder G, Trebar B, Baur F, Schweizer R, Ranke MB. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Clin Endocrinol (Oxf) 2008; 68(4): 567-72.
  19. Stallings-Mann ML, Ludwiczak RL, Klinger KW, Rottman F. Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism. Proc Natl Acad Sci U S A 1996; 93(22): 12394-9.
  20. Padidela R, Bryan SM, Abu-Amero S, Hudson-Davies RE, Achermann JC, Moore GE, et al. The growth hormone receptor gene deleted for exon three (GHRd3) polymorphism is associated with birth and placental weight. Clin Endocrinol (Oxf) 2012; 76(2): 236-40.
  21. Binder G, Baur F, Schweizer R, Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 2006; 91(2): 659-64.
  22. Gao L, Zheng Z, Cao L, Shen S, Yang Y, Zhao Z, et al. The growth hormone receptor (GHR) exon 3 polymorphism and its correlation with metabolic profiles in obese Chinese children. Pediatr Diabetes 2011; 12(4 Pt 2): 429-34.
  23. Montefusco L, Filopanti M, Ronchi CL, Olgiati L, La-Porta C, Losa M, et al. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. Clin Endocrinol (Oxf) 2010; 72(5): 661-7.